glaxo glx stock ulcer report share glaxo hold plc fell follow report england journal medicine antibiotic able treat ulcer threaten glaxo dlr antiulcer drug zantac analyst glaxo trade volume share share smithkline beckman skb maker popular antiulcer drug tagamet fell raise possiblity entirely therapy ulcer attack core glaxo worldwide business zantac david maccallum analyst follow glaxo hambrecht quist zantac world prescribe drug annual sale dollar account pct glaxo earn maccallum perception zantac therapy choice ulcer glaxo sale profit decline tina rizopuolos analyst alexander laing kshnk rizopuolos england journal article lead university toronto researcher conclude study child gastric disease bacteria gastritis ulcer editorial issue medical journal richard hornick university rochester school medicine review study use antibiotic treat ulcer rizopuolos hornick conclude bacteria ulcer relationship excite intrigue study direct causal effect ulcer happen stomach protective line erode expose underlie inflame tissue unknown actually cause process stomach acid exacerbate ulcer antacid commonly alleviate ulcer tagamet zantac drug prevent release hormone histamine stomach trigger acid secretion people run sell glaxo analyst rizopuolos time displace tagamet zantacthose drug prescribe physician time add 
